

1 **Reduced Vancomycin Susceptibility in an *in vitro* Catheter-Related Biofilm Model**
2 **Correlates with Poor Therapeutic Outcomes in Experimental Endocarditis due to**
3 **Methicillin-Resistant *Staphylococcus aureus***

4
5 **Wessam Abdel Hady¹, Arnold S. Bayer^{1,2}, Kati Seidl³, Cynthia C. Nast^{2,4},**
6 **Megan R. Kiedrowski⁵, Alexander R. Horswill⁵, Michael R. Yeaman^{1,2},**
7 **and Yan Q. Xiong^{1,2*}**

8
9
10 **Running title: Vancomycin and *in vitro* MRSA biofilm model**

11
12 ¹ Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA

13 ² David Geffen School of Medicine at UCLA, Los Angeles, CA

14 ³ University Hospital Zurich, University of Zurich, Switzerland

15 ⁴ Cedars-Sinai Medical Center, Los Angeles, CA

16 ⁵ Carver College of Medicine, University of Iowa, Iowa City, Iowa

17
18 *Corresponding author: Dr. Yan Q. Xiong

19 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center

20 1124 West Carson Street, Bldg RB-2, Torrance, CA, 90502

21 Phone: +1 310 222 3545

22 Fax: + 1 310 782 2016

23 E-mail: yxiong@ucla.edu

24

25

26 **Abstract**

27

28 *Staphylococcus aureus* (SA) is the most common cause of endovascular infections,
29 including catheter sepsis and infective endocarditis (IE). Vancomycin (VAN) is the primary
30 choice for treatment of methicillin-resistant SA (MRSA) infections. However, high rates of VAN
31 treatment failure in MRSA infections caused by “VAN-susceptible” strains have been
32 increasingly reported. Biofilm-associated MRSA infections are especially prone to clinical
33 antibiotic failures. The present studies examined potential relationships between MRSA
34 susceptibility to VAN in biofilms *in vitro* and non-susceptibility to VAN in endovascular
35 infection *in vivo*. Using ten VAN-susceptible MRSA bloodstream isolates previously
36 investigated for VAN responsiveness in experimental IE, we studied mechanism(s) of such *in*
37 *vivo* VAN resistance, including: **i)** VAN binding to MRSA; **ii)** the impact of VAN on biofilm
38 formation and biofilm composition; **iii)** VAN efficacy in an *in vitro* catheter-related biofilm
39 model; and **iv)** cell-wall thickness. As a group, the five strains previously categorized as VAN
40 Non-Responders (Non-Rsp) in the experimental IE differed from the five Responders (Rsp) in
41 terms of lower VAN binding, increased biofilm formation, higher survival in the presence of
42 VAN within biofilms in presence or absence of catheters, and greater biofilm reduction with
43 proteinase K treatment. Interestingly, sub-MICs of VAN significantly promoted biofilm
44 formation only in Non-Rsp isolates. Cell wall thickness was similar among all MRSA strains.
45 These results suggest that sub-lethal VAN levels induce biofilm formation and reduce efficacy of
46 VAN in the *in vitro* catheter-associated biofilms may contribute to suboptimal treatment
47 outcomes in endovascular infections caused by “VAN-susceptible” MRSA strains.

48 Abstract word count – 248 (250 limit)

49

50 **Introduction**

51 *Staphylococcus aureus* is the leading cause of biofilm-associated infections such as
52 intravascular catheter-related sepsis and endocarditis (IE), which are associated with
53 unacceptably high morbidity, mortality and cost (1, 2). Two key factors have been linked with
54 suboptimal outcomes in treating such invasive *S. aureus* infections: the organism's abilities to
55 develop resistance to multiple antibiotics (e.g., MRSA; VISA; VRSA) (3), and its ability to form
56 biofilms on both native tissues and implanted biomaterials (2). It is well known that *S. aureus*
57 cells within a complex biofilm matrix are refractory to both systemic antimicrobial agents and
58 host immune responses (4-6).

59 Vancomycin (VAN) is the current standard treatment for invasive MRSA infections.
60 However, the relatively high failure rate of VAN treatment against such syndromes is alarming
61 (7-10), especially with infections caused by MRSA strains whose MICs fall within the
62 susceptible range ($\text{MIC} \leq 2 \mu\text{g/ml}$) (11, 12). While the exact mechanisms for such reduced
63 treatment successes remain unclear, reduced VAN accessibility to *S. aureus* cells within biofilms
64 (13) and VAN induction of biofilm formation (14) are intriguing hypotheses.

65 In a recently published investigation, we evaluated the efficacy of VAN against ten
66 MRSA clinical bloodstream isolates in a catheter-induced IE model in rabbits (15). All ten
67 MRSA strains were VAN-susceptible (MICs 0.5-1.0 $\mu\text{g/ml}$) and non-tolerant to this agent *in*
68 *vitro*. However, VAN treatment outcomes versus these strains were dramatically different (15).
69 Thus, despite equivalent *in vivo* virulence profiles, five of these strains were highly susceptible to
70 VAN therapy in this model (Responders [**Rsp**]), while the remaining five isolates were
71 substantially resistant to VAN therapy (Non-Responders [**Non-Rsp**]) (15). Thus, the current

72 study was designed to evaluate mechanism(s) that may contribute to these disparate VAN
73 treatment outcomes previously observed in experimental IE, focusing on biofilm-associated
74 phenotypes and events.

75

76

77 **Materials and Methods**

78

79 **Bacterial strains.** The ten MRSA bloodstream study isolates are shown in **Table 1**; these data
80 have been described in detail previously (15-17). All ten strains had VAN MICs within the
81 susceptible range (0.5-1.0 µg/ml). The five Rsp strains were defined as isolates in which VAN
82 treatment caused $\geq 5 \log_{10}$ CFU mean reduction per gram of vegetations, and $\geq 3 \log_{10}$ CFU mean
83 reductions per gram of kidneys and spleen in a rabbit IE model (15, 17). The five Non-Rsp
84 strains were defined as isolates in which $< 1.5 \log_{10}$ CFU mean reduction per gram of
85 vegetations, kidneys, and spleen due to VAN treatment in the IE model were observed (15, 17).
86 To assure that the phenotypic properties of these 10 strains were maintained upon long-term
87 storage at -80°C , we re-tested a prototypic phenotype (delta-hemolysin production); this
88 phenotype remained identical to those we have previously published (15) (data not shown).

89

90 **Population analyses.** VAN population analyses of two *S. aureus* control strains and the ten
91 MRSA study strains were performed by standard protocols (18, 19). *S. aureus* strains ATCC
92 25923 (non-VISA) and MU50 (known VISA) (20) were used as a negative and positive control
93 isolates, respectively, for this assay. Briefly, an overnight culture of *S. aureus* cells were
94 washed, adjusted to $\text{OD}_{600\text{nm}}$ at 1.000 ($\sim 10^9$ CFU/ml) and diluted in saline to 10^{-6} . Fifteen
95 microliters of the bacterial suspension (from no dilution to 10^{-6}) was placed on Mueller-Hinton
96 broth agar (MHBA) plates containing VAN, ranging from 0.125 to 16 µg/ml to encompass
97 sublethal-to-lethal drug levels. Colonies counts were quantified after 48 h incubation at 37°C ,
98 and the viable count plotted against VAN concentrations to create population analysis profiles
99 (PAP).

100

101 ***In vitro* time-kill curve of VAN.** To mimic human treatment scenarios in which high trough
102 serum concentrations are targeted for severe MRSA infections, VAN at 15 µg/ml was used in
103 timed-kill analyses in cation-adjusted MHB. In these assays, a starting inoculum of 10⁸ CFU/ml
104 early exponential phase cells was used to mirror target tissue counts in IE (15); surviving
105 bacterial colony counts were quantified at 2, 4, 6 and 24 h incubation at 37°C. Results are
106 expressed as the $\Delta\log_{10}$ CFU/ml (\pm SD) as compared to the initial inoculum.

107

108 **VAN binding to MRSA.** VAN binding to MRSA strains was measured using a modified boron
109 dipyrromethene difluoride-labelled VAN strategy (Bodipy[®]FL VAN; Invitrogen Corp., Carlsbad,
110 CA, USA) (21). The maximum excitation and emission spectra of the Bodipy[®]FL VAN are
111 504nm and 511nm, respectively. Briefly, overnight cultured MRSA cells (10⁸ CFU/ml) were
112 exposed to Bodipy[®]FL VAN at 15 µg/ml for 30 min at 37°C in cation-adjusted MHB. The
113 binding of VAN was assayed by quantitative flow cytometry (FACScalibur; Becton-Dickinson)
114 (22, 23). For each sample, 10,000 cells were acquired and analyzed, with data expressed as the
115 proportion of cells exhibiting threshold levels of VAN binding (mean \pm SD of fluorescent cells).

116

117 **Cell wall thickness.** Although the precise mechanisms are not clear, the degree of cell wall
118 thickness of *S. aureus* is felt to play an important role in resistance to VAN killing (24).
119 Therefore, MRSA strains were assessed for cell wall thickness by transmission electron
120 microscopy (25, 26). For each MRSA strain, the cell wall thickness of 100 individual cells was
121 measured at x190,000 magnification (model 100CX; Jeol, Tokyo, Japan), and data was analyzed
122 to determine mean cell wall thickness (\pm SD). All cell wall measurements were performed by
123 one of the authors (C.C.N) blinded as to the identity of the strains.

124

125 **Primary attachment assay.** The initial attachment to biologic surfaces is an important step in
126 biofilm formation, as well as in the subsequent pathogenesis of *S. aureus* biofilm-associated
127 infections. Therefore, we tested the capability of the ten MRSA strains to attach to a polystyrene
128 surface by using the method previously described (27, 28). Briefly, overnight *S. aureus* cultures
129 were adjusted to an OD_{600nm} of 0.5 (~ 10⁸ CFU/ml) and diluted to 10³ CFU/ml. 100 µl of the
130 suspension was spread on Primaria™ tissue culture polystyrene petri dishes (BD Falcon™ REF
131 353803). After 30 min incubation at 37°C, the petri dishes were gently rinsed three times with
132 PBS and then covered with 15 ml of TSB agar. Primary attachment was expressed as the mean
133 percentage of CFU (± SD) remaining on the petri dishes compared to the initial inoculum. Each
134 experiment was repeated three times independently.

135
136 **Biofilm formation under static conditions.** The ability to form biofilms is believed to make
137 microbes more resistant to antibiotics and host defense system. In addition, some investigations
138 have shown that sub-MIC levels of selected antibiotics can actually prompt biofilm formation
139 (29). In this regards, Hsu *et al* (14) have recently reported that sub-MIC levels of VAN can
140 promote MRSA biofilm formation *in vitro*, a process that may have clinical significance. Thus,
141 the degree of biofilm formation under static conditions was determined for our ten MRSA strains
142 in the presence or absence of 0.5x MICs VAN, as described previously (14, 16). Briefly, MRSA
143 strains from fresh blood TSB agar plates were adjusted to a density of 0.5 McFarland standard
144 and diluted 1:10 into BHI supplemented with 0.5% glucose (BHIG; containing ~ 10⁷ CFU/ml).
145 Then, 200 µl of this suspension (with or without 0.5x MICs of VAN) were transferred to flat-
146 bottom 96-well Nunc polystyrene culture plates (Roskilde, Denmark) and incubated at 37 °C for
147 18 h. After incubation, the plates were washed with PBS, air dried, stained with 0.1% safranin
148 (Acros Organics), and then washed with distilled water. The adhering dye was dissolved in 30%

149 acetic acid and absorption was measured at OD_{490nm} to quantify biofilm formation.

150

151 **Biofilm formation under flow conditions.** To test biofilm formation under flow conditions,
152 two randomly selected Rsp and Non-Rsp strain pairs were assessed in an *in vitro* once-through
153 flow cell model (30). Briefly, polycarbonate flow cells (channel dimensions 5 x 35 x 1 mm) with
154 acid-washed glass cover slips serving as a substratum were used. Sterile culture media (2% BHI
155 with 0.4% glucose) was pumped at laminar flow (0.17 ml/min) through a bubble trap, a flow cell,
156 and into a final collection device. The system was inoculated with 1 ml overnight culture of each
157 Rsp or Non-Rsp strain diluted 1:20 in sterile water, and bacteria were allowed to attach for 1 h at
158 22° C before starting flow. After 48 h, biofilms were post-stained using the Syto 9 “live” and
159 Topro-3 “dead” fluorescent stains (Molecular Probes), then visualized by confocal microscopy
160 using a Nikon Eclipse E600 microscope equipped with a Radiance 2100 imaging system®
161 (Biorad). Z series of images were collected, and three-dimensional renderings of the confocal
162 images were generated with Volocity® software (Improvision). Average biomass and thickness
163 of biofilms was determined by the COMSTAT program (31).

164

165 **Biofilm composition.** Biofilms formed by different bacteria have been shown to have distinctly
166 different chemical compositions (i.e., carbohydrate-, protein- or extracellular DNA-dominants)
167 (2, 32). These compositional differences have been described to contribute functionally and
168 structurally to the organization of biofilm (2, 32). Therefore, relative differences in the stability
169 of the biofilms formed by our MRSA study strains were determined as a function of specific
170 biochemical components, using carbohydrate, protein, or DNA dispersal agents (16, 33). In
171 addition, the impact of sub-MIC VAN on such differences was assessed. In brief, the
172 supernatants of 18 h old biofilms generated by MRSA in the presence or absence of 0.5x MICs

173 VAN exposure were replaced by fresh medium supplemented with either: **i)** 10 mM sodium
174 metaperiodate (Alfa Aesar, Ward Hill, MA) to assess relative carbohydrate content; **ii)** 100 µg/ml
175 protease K (Acros Organics) to assess relative protein content; or **iii)** 140 U/ml RNase-free
176 DNase I (Takara Bio Inc., Shiga, Japan) to assess relative DNA content. All incubations were for
177 2 h at 37°C as detailed (16, 33). Media without the above supplements served as respective
178 negative controls. After biochemical dispersal treatments, the biofilms were quantified as
179 described before.

180

181 ***In vitro* catheter-associated biofilm model.** To simulate the *in vivo* scenario of the catheter-
182 induced experimental IE model, an *in vitro* catheter-associated biofilm formation model was
183 used to test the relative capacity of the MRSA strains to form biofilm and to respond to VAN
184 exposure (34). Briefly, sterile 1-cm segments of polyethylene catheters (14-gauge, BD Insyte
185 Autoguard, BD), the same material as was used in the experimental IE model (15), were placed
186 in a 12-well microtiter plate containing 4 ml of BHIG with 5×10^6 CFU/ml of MRSA cells and
187 incubated overnight with shaking (100 rpm) at 37°C. After 24 h incubation, infected catheters (n
188 = 3 for each group) were rinsed with PBS to remove nonadherent *S. aureus*, then placed into a
189 sterile tube containing 5 ml of PBS, and sonicated for three 30 s cycles with a Branson Sonifier
190 450 (power output setting 3; Branson Ultrasonic Corporation, Danbury, Connecticut, USA).
191 After sonication, samples were quantitatively cultured, and the mean (\pm SD) of adherent bacteria
192 then calculated from three independent experiments.

193

194 The same *in vitro* catheter-associated biofilm model was used to assess susceptibility to
195 VAN killing. Catheters covered with established biofilms after the initial overnight incubation as
196 described above were rinsed in PBS, and then transferred to fresh BHIG with or without VAN

197 (15 µg/ml), and incubated with shaking (100 rpm) at 37°C for three days (chosen to mimic the
198 therapy period in the experimental IE model) (15). At daily intervals, parallel catheter
199 preparations were rinsed in PBS and transferred to fresh BHIG with or without VAN (15 µg/ml).
200 At each time point, catheters from each group were recovered and were quantitatively cultured as
201 described above.

202

203 **Statistical analysis.** A Student's *t*-test was used to analyze experimental data and compare
204 means. *P* values of < 0.05 were considered statistically significant.

205

206

207

208 **Results**

209

210 **Population analyses profiles (PAPs).** VAN PAPs of the two control *S. aureus* and ten MRSA
211 strains are shown in **Fig. 1**. As expected, *S. aureus* ATCC 25923 had no sub-populations with
212 decreased VAN susceptibility. In contrast, the VISA MU50 had a notable rightward shift of the
213 survival curve, with large subpopulations that were resistant to VAN. In terms of the 10 study
214 MRSA strains, 9/10 isolates had virtually identical PAP curves, without revealing any VAN-
215 resistant subpopulations (**Fig. 1**). However, one of the Non-Rsp strains, 300-103, had a small
216 subpopulation that grew on the medium containing VAN at 2 µg/ml.

217

218 ***In vitro* VAN time-kill curve.** The mean MRSA densities of the starting inocula in Non-Rsp
219 and Rsp groups were similar ($7.87 \pm 0.10 \log_{10}$ CFU/ml and $7.84 \pm 0.09 \log_{10}$ CFU/ml,
220 respectively). Control cultures without VAN exposure increased $\sim 2 \log_{10}$ CFU/ml for both
221 Non-Rsp and Rsp groups over the 24 h incubation. As a group, the Non-Rsp isolates had
222 significantly less MRSA density reductions at all time-points during the 24 h VAN exposures as
223 compared to Rsp strains (**Fig. 2**; $P < 0.05$).

224

225 **VAN binding.** Overall, the Non-Rsp strains demonstrated significantly less binding to VAN as
226 compared to the Rsp strains (**Fig. 3**; $75.6 \pm 6.4\%$ vs. $82.3 \pm 5.9 \%$, respectively; $P = 0.03$).
227 However, there was no significant correlation between the *in vitro* susceptibility to VAN killing
228 profiles above and binding of VAN (data not shown).

229

230 **Cell wall thickness.** All ten MRSA strains exhibited similar cell wall thickness profiles. The
231 means (\pm SD) of cell wall thickness for the Non-Rsp and Rsp groups are 24.30 ± 2.34 nm and
232 26.13 ± 2.83 nm, respectively.

233

234 **Primary attachment.** Primary attachment assays revealed no significant initial binding
235 differences between the Non-Rep and Rep groups to polystyrene surface ($88.6 \pm 12.9\%$
236 and $83.6 \pm 8.4\%$ of the initial inoculum bound to the polystyrene petri dishes,
237 respectively).

238

239 **Biofilm formation under static conditions.** The capacity of MRSA strains to form biofilms in
240 the presence vs absence of sub-MIC of VAN is summarized in **Fig. 4**. The mean absorbance
241 without VAN exposure for Non-Rsp and Rsp was 1.14 ± 0.51 and 0.78 ± 0.27 , respectively.
242 However, this difference did not reach statistical significance. Interestingly, in the presence of
243 $0.5 \times$ MIC of VAN, four of the five Non-Rsp MRSA strains exhibited significantly enhanced
244 biofilm formation vs. their respective controls ($P < 0.05$). In contrast, none of the Rsp strains
245 significantly increased biofilm formation in the presence of sub-MICs VAN exposure as
246 compared to their respective controls (**Fig. 4**).

247

248 **Biofilm formation under flow conditions.** To verify the static biofilm assay observations, two
249 Non-Rsp and Rsp strain pairs were tested in a flow cell model system (**Fig. 5**). Overall the
250 biofilm growth of these selected pairs paralleled the static assay outcomes described above. For
251 example, strain 300-169 formed a thick, confluent biofilm with an average biomass of 36
252 $\mu\text{m}^3/\mu\text{m}^2$ and an average thickness of $44 \mu\text{m}$ among the strain tested (**Fig. 5**), supporting the high
253 levels of biomass observed in the static assay. Similarly, both Rsp strains mirrored the static

254 assay results with poor biofilm capacity in the flow cell system. Strain 010-016 measured a
255 biomass of just $0.0001 \mu\text{m}^3/\mu\text{m}^2$, and the second Rsp strain, 301-188, accumulated slightly more
256 biomass than strain 010-016 ($0.02 \mu\text{m}^3/\mu\text{m}^2$) (**Fig. 5**).

257

258 **Biofilm composition.** The percent reductions in biofilm for the 10 MRSA strains in the presence
259 of sodium metaperiodate, proteinase K and DNase I are shown in **Fig. 6**. Without sub-MIC of
260 VAN exposure, treatment with sodium metaperiodate or DNase I led to a similar reduction of
261 biofilm mass between the Non-Rsp and Rsp groups (**Fig. 6A**). However, the biofilms of the Non-
262 Rsp isolates were reduced by the treatment with proteinase K to a greater extent vs. Rsp strains
263 (mean reductions were $73.1 \pm 17.3\%$ vs. $59.1 \pm 10.4\%$, respectively; $P < 0.05$, **Fig. 6A**). This
264 result suggested that biofilm formation in the Non-Rsp group was more dependent on protein
265 content vs. the Rsp group in the absence of VAN. Sub-MIC of VAN exposure increased
266 carbohydrate, protein and DNA contents in the Non-Rsp group (although these differences did
267 not reach statistical significance), while causing no significant changes in biofilm composition in
268 the Rsp group vs. without VAN exposure (**Fig. 6B**).

269

270 **Activity of VAN within catheter-associated biofilms *in vitro*.** We further assessed the capacity
271 of the ten MRSA strains to form biofilm and the efficacy of VAN on preformed biofilms in the
272 presence of catheters (**Fig. 7**). Without VAN exposure, a similar MRSA density profiles were
273 observed on catheters infected by the Non-Rsp and Rsp MRSA strains based on *S. aureus* counts
274 within catheter biofilms. For instance, at 24 h incubation, the numbers of viable MRSA
275 recovered from catheters colonized with the Non-Rsp and Rsp groups (before VAN exposure)
276 were 7.85 ± 0.29 and $7.56 \pm 0.15 \log_{10}$ CFU/catheter, respectively. By comparing the number of
277 viable bacteria recovered from catheters infected with the strains over additional three days

278 experimental period without VAN exposure, a similar capacity to grow within biofilm was also
279 observed (**Fig. 7**). Taken together, these analyses indicated that the Non-Rsp and Rsp strains had
280 a similar ability to form catheter-associated biofilms (mirroring similar intrinsic virulence in
281 comparing the Non-Rsp and Rsp groups in the experimental IE model) (15).

282

283 In the presence of VAN, the number of viable MRSA cells recovered from catheters
284 infected by all five Rsp isolates was markedly reduced during three days incubation (**Fig. 7**). In
285 addition, this biofilm clearance effect of VAN in the Rsp group reached statistical significance in
286 four of the five Rsp isolates versus respective untreated controls (**Fig. 7**; $P < 0.05$). In contrast,
287 for the Non-Rsp group, VAN did not significantly decrease MRSA counts in any of the five
288 isolates as compared to their respective untreated controls over the same time period (**Fig 7**).

289

290

291 **Discussion**

292

293 VAN remains an important first-line antibiotic for the treatment of serious MRSA
294 infections such as endocarditis (IE). Although the majority of MRSA strains are susceptible to
295 VAN *in vitro* with MICs ≤ 2 $\mu\text{g/ml}$ (35), reports of clinical failure with VAN treatment are
296 relatively frequent (36, 37). For instance, VAN treatment success rates of only 10-20% and 56-
297 77% have been demonstrated for MRSA bacteremia caused by isolates with MICs of 1-2 $\mu\text{g/ml}$
298 and ≤ 0.5 $\mu\text{g/ml}$, respectively (38, 39). The exact mechanism(s) of VAN treatment failure among
299 such “VAN-susceptible” MRSA isolates is not well defined. In this study, we investigated
300 relevant mechanism(s) of such “*in vivo* resistance” to VAN treatment in MRSA endovascular
301 infection. Our results showed interesting parallels among: *i*) increased biofilm formation upon
302 sub-MIC VAN exposure; *ii*) reduced VAN activity in an *in vitro* catheter-associated biofilm
303 model; and *iii*) *in vivo* VAN treatment failure in the catheter-induced experimental IE model
304 (15), using ten MRSA clinical isolates that were all susceptible to VAN *in vitro*.

305

306 Several other notable findings emerged from this investigation. *First*, Rsp isolates were
307 significantly more susceptible to VAN-induced killing than Non-Rsp isolates with respect to
308 VAN interactions with MRSA using *in vitro* conditions approximating key *in vivo* parameters:
309 *i*) utilizing VAN at 15 $\mu\text{g/ml}$ to mirror targeted trough concentrations for severe MRSA
310 infections (40); and *ii*) employing high initial MRSA counts (10^8 CFU/ml) to mirror bacterial
311 densities in the major target tissues in the IE model (e.g., cardiac vegetations) (15). This
312 difference in susceptibility was concordant with previous findings in which a significant positive
313 correlation with VAN staphylocidal effect *in vitro* and VAN therapy success in MRSA
314 bacteremia was demonstrated (39). In addition, we investigated several potential factors that may

315 have contributed to these findings: **i)** as a group, VAN bound significantly less to Non-Rsp
316 isolates vs. the Rsp strains; **ii)** the Non-Rsp strains displayed more extensive *in vitro* biofilm
317 formation in the absence of catheters; **iii)** biochemical analyses revealed a significantly greater
318 biofilm formation reduction with proteinase K treatment by Non-Rsp vs. Rsp strains; **iv)** sub-
319 MIC VAN exposures significantly enhanced biofilm formation, and substantially and globally
320 increased biofilm composition only in the Non-Rsp group; and **v)** a positive correlation was
321 observed between VAN activity in the *in vitro* catheter-associated biofilm formation model and
322 therapeutic outcomes previously observed in the experimental IE model (15).

323

324 Collectively, these *in vitro* differences above between Non-Rsp vs. Rsp strains provide
325 substantial insights into different outcomes of VAN therapy in both clinical and experimental IE
326 scenarios (15, 38, 39). For instance, the *in vitro* biofilm formation assay confirmed that the
327 biofilm-forming capacities of the Non-Rsp strains were significantly enhanced following sub-
328 MIC VAN exposure, an outcome not observed in the Rsp group. This observation raises the
329 notion that, in the IE model, VAN-enhanced biofilm formation may occur within cardiac
330 vegetations, where some deeply embedded MRSA cells are likely to be exposed to sub-lethal
331 VAN during the course of therapy in the IE model. This scenario may well contribute to VAN
332 treatment failures in this model. However, the exact mechanisms involved in enhancing biofilm
333 formation upon sub-MIC of VAN exposure in Non-Rsp strains are not well known. In contrast
334 to *S. epidermidis*, few studies have examined the effect of sub-MIC antibiotics on *S. aureus*
335 biofilm formation (14, 41-44). One recent study reported that sub-MIC VAN can enhance *S.*
336 *aureus* cell lysis, extracellular DNA release, and promote biofilm formation (14). We have tested
337 the effect of sub-MIC of VAN on autolysis, but no differences were found between the Non-Rsp
338 and Rsp groups (data not shown). In addition, Rachid *et al* have reported that sub-inhibitory

339 concentrations of tetracycline and quinupristin/dalfopristin increase *ica* expression and
340 subsequent biofilm formation in *S. epidermidis* (45). Taken together, biofilm formation appears
341 to be triggerable by certain antibiotic exposures in both coagulase-positive and coagulase-
342 negative staphylococci, albeit by different mechanisms. Studies to further examine the
343 phenotypic and genotypic impacts of sub-MIC of VAN upon biofilm formation are in progress in
344 our laboratory.

345

346 The data also demonstrated that biofilms formed by Non-Rsp and Rsp isolates have
347 different vulnerabilities to proteinase as compared to carbohydrate and DNA perturbation. It has
348 been reported that PNAG, the major polysaccharide component of the *S. aureus* biofilm matrix,
349 does not limit VAN penetration (46). However, to our knowledge, the role of biofilm protein
350 content in the context of VAN penetration or intra-biofilm bacterial clearances has not been
351 defined. The major fibronectin binding proteins (FnBPA and FnBPB) are induced with sub-MIC
352 VAN (14); these surface proteins are known to be essential for MRSA biofilm formation (47),
353 and could be a factor in the increased susceptibility of Non-Rsp strains to proteinase K (Fig. 6).
354 An alternate explanation could be that exposure to sub-MIC VAN may affect the expression of
355 genes involved in biofilm production in a differential manner across distinct MRSA strains.

356

357 The *in vitro* catheter-associated biofilm model provided a mean to assess VAN treatment
358 in a setting akin to *in vivo* endovascular infections. Importantly, all ten MRSA strains formed
359 similar quantities of biofilm in the *in vitro* biofilm model based on bacterial counts. This
360 comparable biofilm formation between the two groups parallels the similar intrinsic virulence of
361 the Non-Rsp and Rsp strains in the IE model (based on similar target tissue bacterial counts)
362 (15). However, in some strains, MRSA densities (\log_{10} CFU) within catheter biofilms in the

363 absence of VAN tended not to parallel the static biofilm assay (OD_{490nm}). For example, while
364 isolate 077-107 produced more biofilm mass than other Non-Rsp isolates (Fig. 3), its bacterial
365 density within the catheter biofilms was not higher than other Non-Rsp strains (Fig. 7). Such
366 differences between the results of the two assays may be due to difference in: i) chemical
367 composition of materials used in the assays (polyethylene vs. polystyrene); ii) biofilm growth
368 conditions (shaking vs. static) and/or iii) presence vs. absence of catheters, which may alter cell
369 attachment or biofilm accumulation profiles. Consistent with the differential VAN treatment
370 outcomes in the IE model, VAN exposure substantially reduced bacterial counts within
371 established catheter biofilms infected by all five Rsp isolates ($P < 0.05$ for four of five Rsp
372 isolates). In contrast, there were no significant differences in MRSA clearance by VAN within
373 catheter biofilms formed by Non-Rsp isolates. The precise mechanism(s) of this suboptimal
374 MRSA clearance by VAN within Non-Rsp-induced catheter biofilms are not well understood,
375 but will likely include their distinct biofilm compositions, limitations of VAN biofilm
376 penetration, the evolution of “persister” cell populations within the depths of the biofilm, and/or
377 VAN-induced enhancement of biofilm formation (13, 48-50).

378

379 In conclusion, our results suggest that several factors, including *in vitro* VAN activity,
380 VAN binding, and the impact of VAN on biofilm formation and the efficacy of VAN within
381 catheter-associated biofilms may contribute to differential VAN treatment outcomes in
382 experimental IE. The results presented herein translated important observations from *in vitro* to
383 *in vivo* conditions. Given the importance of biofilm phenotypes in persistent bacteremia and
384 endocarditis, these insights may also be useful as surrogate predictors of clinical outcomes in
385 VAN treatment of human MRSA infections. However, additional mechanistic studies are needed
386 to better understand the precise factors responsible for VAN treatment failures in invasive

387 MRSA infections caused strains exhibiting a VAN "susceptible" phenotype *in vitro*.

388

389

390

391 **Acknowledgments.**

392

393 This study was funded in part by American Heart Association, Grant-In-Aid
394 (09GRNT2180065 to YQX), and research grants from the National Institutes of Health
395 (R21AI097657 to Y.Q.X; RO1AI-39108 to A.S.B; Project 3 of PO1 AI083211 to A.R.H; and
396 RO1AI-39001 to M.R.Y).

397

398

399 **References**

400

- 401 1. **Kiedrowski, M. R., and Horswill, A. R.** 2011. New approaches for treating
402 staphylococcal biofilm infections. *Annals of the New York Academy of Sciences*
403 **1241**:104-121.
- 404 2. **Otto, M.** 2008. Staphylococcal biofilms. *Current topics in microbiology and immunology*
405 **322**:207-228.
- 406 3. **Chang, S., Sievert, D. M., Hageman, J. C., Boulton, M. L., Tenover, F. C., Downes,**
407 **F. P., Shah, S., Rudrik, J. T., Pupp, G. R., Brown, W. J., Cardo, D., and Fridkin, S.**
408 **K.** 2003. Infection with vancomycin-resistant *Staphylococcus aureus* containing the
409 vanA resistance gene. *The New England journal of medicine* **348**:1342-1347.
- 410 4. **Melchior, M. B., Fink-Gremmels, J., and Gastra, W.** 2006. Comparative assessment
411 of the antimicrobial susceptibility of *Staphylococcus aureus* isolates from bovine mastitis
412 in biofilm versus planktonic culture. *Journal of veterinary medicine* **53**:326-332.
- 413 5. **Vlastarakos, P. V., Nikolopoulos, T. P., Maragoudakis, P., Tzagaroulakis, A., and**
414 **Ferekidis, E.** 2007. Biofilms in ear, nose, and throat infections: how important are they?
415 *The Laryngoscope* **117**:668-673.
- 416 6. **Kania, R. E., Lamers, G. E., Vonk, M. J., Dorpmans, E., Struik, J., Tran Ba Huy, P.,**
417 **Hiemstra, P., Bloemberg, G. V., and Grote, J. J.** 2008. Characterization of mucosal
418 biofilms on human adenoid tissues. *The Laryngoscope* **118**:128-134.
- 419 7. **Fusco, D. N., Alexander, E. L., Weisenberg, S. A., Mediavilla, J. R., Kreiswirth, B.**
420 **N., Schuetz, A. N., Jenkins, S. G., and Rhee, K. Y.** 2009. Clinical failure of
421 vancomycin in a dialysis patient with methicillin-susceptible vancomycin-heteroresistant
422 *S. aureus*. *Diagnostic microbiology and infectious disease* **65**:180-183.

- 423 8. **Moise, P. A., Forrest, A., Birmingham, M. C., and Schentag, J. J.** 2002. The efficacy
424 and safety of linezolid as treatment for *Staphylococcus aureus* infections in
425 compassionate use patients who are intolerant of, or who have failed to respond to,
426 vancomycin. *The Journal of antimicrobial chemotherapy* **50**:1017-1026.
- 427 9. **Moise, P. A., and Schentag, J. J.** 2000. Vancomycin treatment failures in
428 *Staphylococcus aureus* lower respiratory tract infections. *International journal of*
429 *antimicrobial agents* **16 Suppl 1**:S31-34.
- 430 10. **Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A.,**
431 **and Moellering, R. C., Jr.** 2004. Accessory gene regulator group II polymorphism in
432 methicillin-resistant *Staphylococcus aureus* is predictive of failure of vancomycin
433 therapy. *Clin Infect Dis* **38**:1700-1705.
- 434 11. **Yamaki, J., Lee, M., Shriner, K. A., and Wong-Beringer, A.** 2011. Can clinical and
435 molecular epidemiologic parameters guide empiric treatment with vancomycin for
436 methicillin-resistant *Staphylococcus aureus* infections? *Diagnostic microbiology and*
437 *infectious disease* **70**:124-130.
- 438 12. **Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo,**
439 **D., Ortega, M., Lopez, J., and Mensa, J.** 2008. Influence of vancomycin minimum
440 inhibitory concentration on the treatment of methicillin-resistant *Staphylococcus aureus*
441 bacteremia. *Clin Infect Dis* **46**:193-200.
- 442 13. **Singh, R., Ray, P., Das, A., and Sharma, M.** 2010. Penetration of antibiotics through
443 *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. *The Journal of*
444 *antimicrobial chemotherapy* **65**:1955-1958.
- 445 14. **Hsu, C. Y., Lin, M. H., Chen, C. C., Chien, S. C., Cheng, Y. H., Su, I. N., and Shu, J.**
446 **C.** 2011. Vancomycin promotes the bacterial autolysis, release of extracellular DNA, and

- 447 biofilm formation in vancomycin-non-susceptible *Staphylococcus aureus*. FEMS
448 immunology and medical microbiology **63**:236-247.
- 449 15. **Seidl, K., Chen, L., Bayer, A. S., Hady, W. A., Kreiswirth, B. N., and Xiong, Y. Q.**
450 2011. Relationship of *agr* expression and function with virulence and vancomycin
451 treatment outcomes in experimental endocarditis due to methicillin-resistant
452 *Staphylococcus aureus*. Antimicrobial agents and chemotherapy **55**:5631-5639.
- 453 16. **Seidl, K., Bayer, A. S., Fowler, V. G., Jr., McKinnell, J. A., Abdel Hady, W.,**
454 **Sakoulas, G., Yeaman, M. R., and Xiong, Y. Q.** 2011. Combinatorial phenotypic
455 signatures distinguish persistent from resolving methicillin-resistant *Staphylococcus*
456 *aureus* bacteremia isolates. Antimicrobial agents and chemotherapy **55**:575-582.
- 457 17. **Seidl, K., Bayer, A. S., McKinnell, J. A., Ellison, S., Filler, S. G., and Xiong, Y. Q.**
458 2011. *In vitro* endothelial cell damage is positively correlated with enhanced virulence
459 and poor vancomycin responsiveness in experimental endocarditis due to methicillin-
460 resistant *Staphylococcus aureus*. Cellular microbiology **13**:1530-1541.
- 461 18. **Moore, M. R., Perdreau-Remington, F., and Chambers, H. F.** 2003. Vancomycin
462 treatment failure associated with heterogeneous vancomycin-intermediate *Staphylococcus*
463 *aureus* in a patient with endocarditis and in the rabbit model of endocarditis.
464 Antimicrobial agents and chemotherapy **47**:1262-1266.
- 465 19. **Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S. J., Proctor, R. A., Sahl, H. G.,**
466 **Schrenzel, J., Xiong, Y. Q., and Bayer, A. S.** 2008. Failures in clinical treatment of
467 *Staphylococcus aureus* infection with daptomycin are associated with alterations in
468 surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrobial
469 agents and chemotherapy **52**:269-278.

- 470 20. **Aeschlimann, J. R., Hershberger, E., and Rybak, M. J.** 1999. Analysis of vancomycin
471 population susceptibility profiles, killing activity, and postantibiotic effect against
472 vancomycin-intermediate *Staphylococcus aureus*. *Antimicrobial agents and*
473 *chemotherapy* **43**:1914-1918.
- 474 21. **Lemaire, S., Kosowska-Shick, K., Julian, K., Tulkens, P. M., Van Bambeke, F., and**
475 **Appelbaum, P. C.** 2008. Activities of antistaphylococcal antibiotics towards the
476 extracellular and intraphagocytic forms of *Staphylococcus aureus* isolates from a patient
477 with persistent bacteraemia and endocarditis. *Clin Microbiol Infect* **14**:766-777.
- 478 22. **Xiong, Y. Q., Willard, J., Yeaman, M. R., Cheung, A. L., and Bayer, A. S.** 2006.
479 Regulation of *Staphylococcus aureus* alpha-toxin gene (*hla*) expression by *agr*, *sarA*, and
480 *sae* *in vitro* and in experimental infective endocarditis. *The Journal of infectious diseases*
481 **194**:1267-1275.
- 482 23. **Xiong, Y. Q., Van Wamel, W., Nast, C. C., Yeaman, M. R., Cheung, A. L., and**
483 **Bayer, A. S.** 2002. Activation and transcriptional interaction between *agr RNAlI* and
484 *RNAlII* in *Staphylococcus aureus in vitro* and in an experimental endocarditis model. *The*
485 *Journal of infectious diseases* **186**:668-677.
- 486 24. **Rose, W. E., Knier, R. M., and Hutson, P. R.** 2010. Pharmacodynamic effect of clinical
487 vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate
488 *Staphylococcus aureus*. *The Journal of antimicrobial chemotherapy* **65**:2149-2154.
- 489 25. **Yang, S. J., Nast, C. C., Mishra, N. N., Yeaman, M. R., Fey, P. D., and Bayer, A. S.**
490 2010. Cell wall thickening is not a universal accompaniment of the daptomycin
491 nonsusceptibility phenotype in *Staphylococcus aureus*: evidence for multiple resistance
492 mechanisms. *Antimicrobial agents and chemotherapy* **54**:3079-3085.

- 493 26. **Mishra, N. N., McKinnell, J., Yeaman, M. R., Rubio, A., Nast, C. C., Chen, L.,**
494 **Kreiswirth, B. N., and Bayer, A. S.** 2011. *In vitro* cross-resistance to daptomycin and
495 host defense cationic antimicrobial peptides in clinical methicillin-resistant
496 *Staphylococcus aureus* isolates. *Antimicrobial agents and chemotherapy* **55**:4012-4018.
- 497 27. **Lei, M. G., Cue, D., Roux, C. M., Dunman, P. M., and Lee, C. Y.** 2011. Rsp inhibits
498 attachment and biofilm formation by repressing *fnbA* in *Staphylococcus aureus* MW2.
499 *Journal of bacteriology* **193**:5231-5241.
- 500 28. **Houston, P., Rowe, S. E., Pozzi, C., Waters, E. M., and O'Gara, J. P.** 2011. Essential
501 role for the major autolysin in the fibronectin-binding protein-mediated *Staphylococcus*
502 *aureus* biofilm phenotype. *Infection and immunity* **79**:1153-1165.
- 503 29. **Kaplan, J. B.** 2011. Antibiotic-induced biofilm formation. *The International journal of*
504 *artificial organs* **34**:737-751.
- 505 30. **Kiedrowski, M. R., Kavanaugh, J. S., Malone, C. L., Mootz, J. M., Voyich, J. M.,**
506 **Smeltzer, M. S., Bayles, K. W., and Horswill, A. R.** 2011. Nuclease modulates biofilm
507 formation in community-associated methicillin-resistant *Staphylococcus aureus*. *PLoS*
508 *One* **6**:e26714.
- 509 31. **Heydorn, A., Nielsen, A. T., Hentzer, M., Sternberg, C., Givskov, M., Ersboll, B. K.,**
510 **and Molin, S.** 2000. Quantification of biofilm structures by the novel computer program
511 COMSTAT. *Microbiology (Reading, England)* **146 (Pt 10)**:2395-2407.
- 512 32. **Mann, E. E., and Wozniak, D. J.** 2012. Pseudomonas biofilm matrix composition and
513 niche biology. *FEMS microbiology reviews* **36**:893-916.
- 514 33. **Izano, E. A., Amarante, M. A., Kher, W. B., and Kaplan, J. B.** 2008. Differential roles
515 of poly-N-acetylglucosamine surface polysaccharide and extracellular DNA in

- 516 *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. Applied and
517 environmental microbiology **74**:470-476.
- 518 34. **Weiss, E. C., Spencer, H. J., Daily, S. J., Weiss, B. D., and Smeltzer, M. S.** 2009.
519 Impact of *sarA* on antibiotic susceptibility of *Staphylococcus aureus* in a catheter-
520 associated *in vitro* model of biofilm formation. Antimicrobial agents and chemotherapy
521 **53**:2475-2482.
- 522 35. **Bland, C. M., Porr, W. H., Davis, K. A., and Mansell, K. B.** 2010. Vancomycin MIC
523 susceptibility testing of methicillin-susceptible and methicillin-resistant *Staphylococcus*
524 *aureus* isolates: a comparison between Etest(R) and an automated testing method.
525 Southern medical journal **103**:1124-1128.
- 526 36. **Kollef, M. H.** 2007. Limitations of vancomycin in the management of resistant
527 staphylococcal infections. Clin Infect Dis **45 Suppl 3**:S191-195.
- 528 37. **Stevens, D. L.** 2006. The role of vancomycin in the treatment paradigm. Clin Infect Dis
529 **42 Suppl 1**:S51-57.
- 530 38. **Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., Jr.,**
531 **and Eliopoulos, G. M.** 2004. Relationship of MIC and bactericidal activity to efficacy of
532 vancomycin for treatment of methicillin-resistant *Staphylococcus aureus* bacteremia.
533 Journal of clinical microbiology **42**:2398-2402.
- 534 39. **Moise, P. A., Sakoulas, G., Forrest, A., and Schentag, J. J.** 2007. Vancomycin *in vitro*
535 bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant
536 *Staphylococcus aureus* bacteremia. Antimicrobial agents and chemotherapy **51**:2582-
537 2586.
- 538 40. **Patel, N., Pai, M. P., Rodvold, K. A., Lomaestro, B., Drusano, G. L., and Lodise, T.**
539 **P.** 2011. Vancomycin: we can't get there from here. Clin Infect Dis **52**:969-974.

- 540 41. **Dunne, W. M., Jr.** 1990. Effects of subinhibitory concentrations of vancomycin or
541 cefamandole on biofilm production by coagulase-negative staphylococci. *Antimicrobial*
542 *agents and chemotherapy* **34**:390-393.
- 543 42. **Cargill, J. S., and Upton, M.** 2009. Low concentrations of vancomycin stimulate
544 biofilm formation in some clinical isolates of *Staphylococcus epidermidis*. *Journal of*
545 *clinical pathology* **62**:1112-1116.
- 546 43. **Chang, Y. M., Jeng, W. Y., Ko, T. P., Yeh, Y. J., Chen, C. K., and Wang, A. H.** 2010.
547 Structural study of TcaR and its complexes with multiple antibiotics from *Staphylococcus*
548 *epidermidis*. *Proceedings of the National Academy of Sciences of the United States of*
549 *America* **107**:8617-8622.
- 550 44. **Mirani, Z. A., and Jamil, N.** 2011. Effect of sub-lethal doses of vancomycin and
551 oxacillin on biofilm formation by vancomycin intermediate resistant *Staphylococcus*
552 *aureus*. *Journal of basic microbiology* **51**:191-195.
- 553 45. **Rachid, S., Ohlsen, K., Witte, W., Hacker, J., and Ziebuhr, W.** 2000. Effect of
554 subinhibitory antibiotic concentrations on polysaccharide intercellular adhesin expression
555 in biofilm-forming *Staphylococcus epidermidis*. *Antimicrobial agents and chemotherapy*
556 **44**:3357-3363.
- 557 46. **Jefferson, K. K., Goldmann, D. A., and Pier, G. B.** 2005. Use of confocal microscopy
558 to analyze the rate of vancomycin penetration through *Staphylococcus aureus* biofilms.
559 *Antimicrobial agents and chemotherapy* **49**:2467-2473.
- 560 47. **O'Neill, E., Pozzi, C., Houston, P., Humphreys, H., Robinson, D. A., Loughman, A.,**
561 **Foster, T. J., and O'Gara, J. P.** 2008. A novel *Staphylococcus aureus* biofilm
562 phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. *Journal of*
563 *bacteriology* **190**:3835-3850.

- 564 48. **Mathur, T., Singhal, S., Khan, S., Upadhyay, D., Fatma, T., and Rattan, A.** 2005.
565 Adverse effect of staphylococci slime on *in vitro* activity of glycopeptides. Japanese
566 journal of infectious diseases **58**:353-357.
- 567 49. **Singh, R., Ray, P., Das, A., and Sharma, M.** 2010. Penetration of antibiotics through
568 *Staphylococcus aureus* and *Staphylococcus epidermidis* biofilms. The Journal of
569 antimicrobial chemotherapy **65**:1955-1958.
- 570 50. **Kostenko, V., Ceri, H., and Martinuzzi, R. J.** 2007. Increased tolerance of
571 *Staphylococcus aureus* to vancomycin in viscous media. FEMS immunology and medical
572 microbiology **51**:277-288.
- 573
574
575

576 **Table 1. Clinical methicillin-resistant *Staphylococcus aureus* strains used in this study**

Strain	Genotype	VAN MIC ($\mu\text{g/ml}$)	VAN response in IE model ^a
300-087	<i>agr</i> -I, <i>SCCmec</i> IV, <i>spa</i> -NEW4, CC45	0.5	Non-Responder
300-169	<i>agr</i> -I, <i>SCCmec</i> IV, <i>spa</i> -NEW1, CC45	0.5	Non-Responder
324-136	<i>agr</i> -I, <i>SCCmec</i> IV, <i>spa</i> -NEW5, CC45	0.5	Non-Responder
300-103	<i>agr</i> -I, <i>SCCmec</i> IV, <i>spa</i> -NEW4, CC45	0.5	Non-Responder
300-246	<i>agr</i> -II, <i>SCCmec</i> I, <i>spa</i> -385, CC5	0.5	Non-Responder
301-188	<i>agr</i> -I, <i>SCCmec</i> IV, <i>spa</i> -NEW1, CC45	0.5	Responder
010-016	<i>agr</i> -II, <i>SCCmec</i> II, <i>spa</i> -2, CC5	1.0	Responder
077-107	<i>agr</i> -II, <i>SCCmec</i> II, <i>spa</i> -2, CC5	1.0	Responder
088-180	<i>agr</i> -II, <i>SCCmec</i> II, <i>spa</i> -2, CC5	0.5	Responder
088-237	<i>agr</i> -II, <i>SCCmec</i> II, <i>spa</i> -2, CC5	0.5	Responder

577

578 ^a. Vancomycin response in an experimental endocarditis (IE) model as previously described
579 (15). See Methods and Materials section for further descriptions

580

581

582

583 **Figures**

584 **Figure 1.** Population analyses of two control *S. aureus* strains ATCC 25923 (\diamond) and MU50 (\blacksquare)
585 upon exposure to a range of VAN concentrations (0-16 $\mu\text{g/ml}$) are shown in Panel A. VAN
586 population analyses of ten MRSA study strains are shown in Panel B (Non-Responders) and C
587 (Responders). Non-responders: \blacklozenge 300-087; \blacksquare 300-169; \blacktriangle 324-136; \times 300-103; \circ 300-246;
588 Responders: \blacklozenge 301-188; \blacksquare 010-016; \blacktriangle 077-107; \times 088-180; \circ 088-237. These data represent the
589 means (\pm SD) for two separate assays.

590

591 **Figure 2.** *In vitro* time-kill curve of VAN (15 $\mu\text{g/ml}$) vs 10 MRSA study strains at high initial
592 inoculum ($\sim 10^8$ CFU/ml) using exponential phase cells. Data are expressed as $\Delta \log_{10}$ CFU/ml
593 (\pm SD) at 2, 4, 6 and 24 h incubation vs. initial inoculum. Non-Rsp control: white; Non-Rsp with
594 VAN exposure: black; Rsp control: light gray; Rsp with VAN exposure: dark gray. * $P < 0.05$
595 between Non-Rsp vs. Rsp group comparisons with VAN exposure.

596

597 **Figure 3.** *In vitro* VAN binding of the ten MRSA study strains, using Bodipy-labeled VAN. The
598 mean of VAN binding for each group is indicated by a horizontal dashed line.

599

600 **Figure 4.** Biofilm formation of the ten MRSA strains under static condition with (\blacksquare) and without
601 (\square) 0.5x MIC of VAN exposure by measuring the absorbance values ($A_{490\text{nm}} \pm$ SD). * $P < 0.05$
602 vs. their respective controls without VAN exposure.

603

604 **Figure 5.** Biofilm formation of the two selected Non-Rsp and Rsp strain pair under flow
605 conditions. Confocal microscopy was used to obtain images of MRSA isolates grown in a flow
606 cell biofilm model.

607

608 **Figure 6.** Biofilm stability of pre-formed biofilm by the ten MRSA strains following sodium
609 metaperiodate, proteinase K or DNase I treatment (as quantified by the percent of A_{490nm}
610 reduction vs. controls). **Panel A:** without VAN exposure; **Panel B:** with 0.5x MIC VAN
611 exposure during the overnight biofilm formation. □: Non-Rsp group; ■ Rsp group. * $P < 0.05$ vs.
612 Non-Rsp group.

613

614 **Figure 7.** Effect of VAN (15 $\mu\text{g/ml}$) in the *in vitro* catheter-associated biofilm formation model.
615 Catheters infected with ten MRSA strains without VAN exposure (□) and with VAN exposure
616 (■) were harvested at daily intervals. The MRSA counts are measured in comparisons of the
617 changes of \log_{10} CFU/catheter vs. initial density for each strain. D1, D2 and D3 represent one,
618 two and three days with/without VAN exposure on established biofilm, respectively. * $P < 0.05$
619 vs. respective controls without VAN exposure.

620

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

